Aliskiren
- Generic Name
- Aliskiren
- Brand Names
- Rasilez, Tekturna, Tekturna Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C30H53N3O6
- CAS Number
- 173334-57-1
- Unique Ingredient Identifier
- 502FWN4Q32
- Background
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.
- Indication
Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.
- Associated Conditions
- Hypertension
- Associated Therapies
- -
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2013-11-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1639
- Registration Number
- NCT00894387
- Locations
- 🇹🇷
Novartis Investigative Site, Talas / Kayseri, Turkey
Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2013-05-17
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 41
- Registration Number
- NCT00881439
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
Aliskiren for Immunoglobulin A (IgA) Nephropathy
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 22
- Registration Number
- NCT00870493
- Locations
- 🇭🇰
Prince of Wales Hospital, Shatin, Hong Kong
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal
- Conditions
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 822
- Registration Number
- NCT00865020
- Locations
- 🇻🇪
Investigative Site, Caracas, Venezuela
🇭🇺Invesitagtive Site, Budapest, Hungary
The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT00856960
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 613
- Registration Number
- NCT00853827
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 7064
- Registration Number
- NCT00853658
- Locations
- 🇻🇪
Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela
Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise
- Conditions
- Interventions
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 68
- Registration Number
- NCT00819767
- Locations
- 🇬🇧
Investigative Site, Leicester, United Kingdom
Direct Renin Inhibition Effects on Atherosclerotic Biomarkers
- Conditions
- Interventions
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Texas Tech University Health Sciences Center
- Target Recruit Count
- 38
- Registration Number
- NCT00818779
- Locations
- 🇺🇸
Texas Tech University Health Sciences Center, Lubbock, Texas, United States
Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2011-03-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 532
- Registration Number
- NCT00797316
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.